Gene · 1308
Papers3,031
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,031
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa. | Mol Ther Nucleic Acids | 2026 | 42824587 | PubTator, text mining | PubMed |
| Exacerbation of Bullous Pemphigoid following a Closed Bone Fracture in an Elderly Patient: A Case Report. | Case Rep Dermatol | 2026 | 42820212 | PubTator, text mining | PubMed |
| Six Cases of Pemphigoid Nodularis during Treatment with Dipeptidyl Peptidase-4 Inhibitors. | Case Rep Dermatol | 2026 | 42813148 | PubTator, text mining | PubMed |
| Clinical remission despite persistent anti-BP180 antibodies in neonatal pemphigoid. | J Eur Acad Dermatol Venereol | 2026 | 42808694 | PubTator, text mining | PubMed |
| Blistering rash in an elderly patient. | J Hosp Med | 2026 | 42803220 | PubTator, text mining | PubMed |
| Coexistence of Erythrodermic Psoriasis and Bullous Pemphigoid: A Case Report. | Clin Cosmet Investig Dermatol | 2026 | 42770037 | PubTator, text mining | PubMed |
| Immune-Checkpoint-Inhibitor-Related Bullous Pemphigoid During Avelumab Maintenance Therapy in a Patient With Metastatic Renal Pelvic Carcinoma: A Case Report. | IJU Case Rep | 2026 | 42688408 | PubTator, text mining | PubMed |
| Repositioning omalizumab in dermatology: emerging indications and mechanism-based therapeutic insights. | Expert Opin Biol Ther | 2026 | 42664019 | PubTator, text mining | PubMed |
| Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report. | Front Med (Lausanne) | 2026 | 42656375 | PubTator, text mining | PubMed |
| Transcriptomic Profiling Identifies a Subset of Renal Tumors with Overlapping Features of Clear Cell Papillary Renal Cell Tumor and Renal Cell Carcinoma with Fibromyomatous Stroma. | Cancers (Basel) | 2026 | 42650024 | PubTator, text mining | PubMed |
| Machine learning-enabled multi-omics discovery of prognostic biomarkers and signaling targets in pancreatic cancer. | Comput Biol Chem | 2026 | 42617351 | PubTator, text mining | PubMed |
| Bullous Pemphigoid: A Focused Review on Antigen Epitopes. | Exp Dermatol | 2026 | 42598880 | PubTator, text mining | PubMed |
| Anti-BP180 Mucosal Membrane Pemphigoid With a History of Maxillary Carcinoma With Antibodies to 190 kDa Periplakin and 210 kDa Envoplakin: A Case Report. | J Dermatol | 2026 | 42543823 | PubTator, text mining | PubMed |
| Clinical Characterization and Outcomes of Dupilumab for Pemphigoid Gestationis: A Case Series of Five Patients and Literature Review. | Acta Derm Venereol | 2026 | 42516098 | PubTator, text mining | PubMed |
| Chemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Diagnosis of Pemphigoid and Pemphigus: A Comparative Study. | Int J Mol Sci | 2026 | 42511614 | PubTator, text mining | PubMed |
| Clinical and immunological profiles of pemphigoid patients negative for CLEIA and positive for ELISA of BP180 NC16A. | J Dermatol Sci | 2026 | 42486718 | PubTator, text mining | PubMed |
| Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. | Clin Cosmet Investig Dermatol | 2026 | 42483000 | PubTator, text mining | PubMed |
| Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor). | Front Immunol | 2026 | 42459647 | PubTator, text mining | PubMed |
| Novel bacterial hosts and mobile genetic structure of tet(X) variants in tetracycline-contaminated aquatic environment uncovered by culture and long-read metagenomics. | Water Res | 2026 | 42447671 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing Identified a Novel Mutation in an Iranian Patient with Epidermolysis Bullosa. | Iran Biomed J | 2026 | 42418347 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1308/papers